Dr. Yongsheng Jiang 姜永生
Chief Physician, Associate Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, radiotherapy, molecular targeted therapy, and palliative care for lymphoma, lung, breast, cervical, gastric, colorectal, bone and soft tissue, pediatric, nasopharyngeal, and intracranial tumors.
Dr. Jiang holds a medical doctorate from Tongji Medical College, Huazhong University of Science and Technology (2003). A postdoctoral researcher in Japan (2009–2010), Dr. Jiang serves as Deputy Director of the Comprehensive Oncology Department at Tongji Hospital. With 15 years of experience, Dr. Jiang has published over 20 papers and contributed to several oncology textbooks.
Professional roles
- Member, Integrated Oncology Cardiology Branch, China Anti-Cancer Association
- Member, Lymphoma Professional Committee, China South Oncology Clinical Research Association (CSWOG)
- Vice Chair, Lymphoma Expert Committee, Hubei Society of Clinical Oncology (ESCO)
- Standing Committee Member, Lymphoma Professional Committee, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Jiang Yongsheng). Papers usually list the name as Yongsheng Jiang or Jiang Y.
Selected publications
24 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hematology, 2023 (senior author): Survival analysis in patients with follicular dendritic cell sarcoma: a population-based study. PubMed 37732620
- J Thromb Thrombolysis, 2023 (senior author): A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers. PubMed 37462901
- Ann Hematol, 2018 (senior author): Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. PubMed 29086009
- J Neurooncol, 2015 (senior author): Effect of treatment with baicalein on the intracerebral tumor growth and survival of orthotopic glioma models. PubMed 25968345
- Acta Pharmacol Sin, 2014 (first author): Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation. PubMed 25399650
- J Neurooncol, 2013 (first author): Caloric restriction reduces edema and prolongs survival in a mouse glioma model. PubMed 23703297
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion